What is Chimera Bioengineering?
Chimera Bioengineering is a South San Francisco-based biotechnology firm dedicated to revolutionizing cancer treatment through advanced CAR-T cell therapy. The company leverages novel genetic engineering techniques to enhance the efficacy and safety of cell therapies, with a specific focus on overcoming the challenges associated with solid tumors. By developing engineered T-cells designed to target specific tumor antigens, Chimera Bioengineering aims to significantly improve patient outcomes while minimizing adverse effects. Their mission centers on creating a new paradigm in oncology by harnessing the power of the immune system for more effective cancer combat.
How much funding has Chimera Bioengineering raised?
Chimera Bioengineering has raised a total of $385K across 2 funding rounds:
Debt
$150K
Debt
$235K
Debt (2020): $150K with participation from PPP
Debt (2021): $235K led by PPP
What's next for Chimera Bioengineering?
The substantial late-stage funding positions Chimera Bioengineering for accelerated growth and the scaling of its therapeutic pipeline. This capital infusion is expected to fuel further research and development, potentially enabling the company to advance its CAR-T cell therapies through clinical trials and towards market approval. The strategic nature of the recent investment suggests strong confidence from financial backers in Chimera's technology and its potential to disrupt the cancer treatment landscape, paving the way for future commercialization efforts.
See full Chimera Bioengineering company page
